Related Experiment Video
Updated: May 30, 2026
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
Management options in triple-negative breast cancer
Christina A Minami1, Debra U Chung, Helena R Chang
1David Geffen School of Medicine, The University of California at Los Angeles, Los Angeles, California, USA.
Abstract:
Notorious for its poor prognosis and aggressive nature, triple-negative breast cancer (TNBC) is a heterogeneous disease entity. The nature of its biological specificity, which is similar to basal-like cancers, tumors arising in BRCA1 mutation carriers, and claudin-low cancers, is currently being explored in hopes of finding the targets for novel biologics and chemotherapeutic agents. In this review, we aim to give a broad overview of the disease's nomenclature and epidemiology, as well as the basic mechanisms of emerging targeted therapies and their performance in clinical trials to date.
Insights
Triple-negative breast cancer (TNBC) is aggressive and diverse. Research explores its biological links to find new targeted therapies and chemotherapeutic agents for better treatment outcomes.
Area of Science:
- Oncology
- Genetics
- Pharmacology
Background:
- Triple-negative breast cancer (TNBC) presents a significant clinical challenge due to its aggressive behavior and poor prognosis.
- TNBC is a heterogeneous disease with biological characteristics overlapping with basal-like cancers, BRCA1-mutated tumors, and claudin-low cancers.
Purpose of the Study:
- To provide a comprehensive overview of triple-negative breast cancer (TNBC).
- To explore the nomenclature, epidemiology, and biological specificity of TNBC.
- To review emerging targeted therapies and their clinical trial performance.
Main Methods:
- Literature review of TNBC nomenclature and epidemiology.
- Analysis of biological similarities between TNBC subtypes.
- Summary of clinical trial data for novel targeted agents.
Main Results:
- TNBC exhibits significant heterogeneity, complicating treatment strategies.
- Biological similarities suggest potential shared therapeutic targets.
- Emerging targeted therapies show variable efficacy in clinical trials.
Conclusions:
- Understanding TNBC's heterogeneity is crucial for developing effective treatments.
- Targeted therapies hold promise but require further clinical validation.
- Continued research into TNBC biology may uncover novel therapeutic avenues.
